Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Fundamentals Continue To Look Strong At Neurocrine Bio

February 6, 2014, Neurocrine Biosciences (NASDAQ:NBIX) reported financial results for the fourth quarter and full year ended 2013. The company reported total revenues in the fourth quarter of $0.73 million, dead-on with our expectations. Revenues have been pegged at around $0.7 million for all four quarters in 2013. Research and development expenses were $8.9 million, around $0.6 million below our estimate. General and administrative expenses of $3.3 million came in essentially right in-line with our model. The company reported a loss of $10.6 million ($0.16 per share) for the quarter, roughly $0.01 better than our expectation of ($0.17) on slightly lower R&D.

For the full year 2013, revenues totaled $2.9 million, a sizable drop from the $53.1 million...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details